Catalog No.
Product Name
Application
Product Information
Citations
-
SARS-CoV-2 PLpro Inhibitor
GZNL-P36 is a potent inhibitor of SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 6.45 nM, demonstrating effective inhibition of SARS-CoV and its variants with EC50 values ranging from 58.2 nM to 2.66 µM. In pharmacokinetic studies conducted in CD-1 mice, GZNL-P36 achieved a peak plasma concentration (Cmax) of 549 ng/mL, a half-life (T1/2) of 1.45 hours, and a bioavailability of 74.7%. This compound exhibits notable antiviral activity in SARS-CoV-2 XXB.1 infections, positioning it as a valuable tool in therapeutic research against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-78 is an inhibitor of the nsp14 protein of SARS-CoV-2, specifically targeting its N7 methyltransferase activity. This compound demonstrates significant antiviral properties and is valuable for research applications in understanding and mitigating SARS-CoV-2 infection. Its mechanism of action makes it a pertinent tool for studying viral replication and pathogenesis, as well as the development of potential therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
ZINC000104379474 is a potent inhibitor of SARS-CoV-2 endoribonuclease. It exhibits significant antiviral activity, making it a valuable tool in the study of SARS-CoV-2 replication mechanisms. This compound is particularly relevant for research focused on COVID-19 therapeutics and the development of novel antiviral strategies. -
SARS-CoV-2 Nsp14 Inhibitor
SARS-CoV-2 nsp14-IN-2 is a selective inhibitor of SARS-CoV-2 Nsp14 methyltransferase, exhibiting an IC50 value of 0.093 µM. This compound demonstrates significant antiviral activity and is stable in plasma and liver S9 fractions. SARS-CoV-2 nsp14-IN-2 is valuable for research applications focusing on COVID-19 and the exploration of therapeutic strategies targeting viral replication mechanisms. -
SARS-CoV Inhibitor
SARS-CoV MPro-IN-1 is a covalent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 40 nM. This compound demonstrates significant anti-SARS-CoV-2 activity in cell culture, with an EC50 of 0.33 μM. SARS-CoV MPro-IN-1 is suitable for research applications focused on COVID-19 and related viral pathogenesis. -
SARS-CoV-2 Inhibitor
10-Hydroxyaloin A is a potent inhibitor of SARS-CoV-2, specifically targeting the main protease (Mpro) of the virus. This compound demonstrates significant binding affinity to the active site of Mpro, which is crucial for viral replication. 10-Hydroxyaloin A is of particular interest in research applications focused on antiviral drug development and understanding the mechanisms of SARS-CoV-2 inhibition. -
SARS-CoV-2 3CLpro Inhibitor
3CPLro-IN-1 is a potent, orally active inhibitor of the SARS-CoV-2 3CLpro with an IC50 of 5.65 μM. 3-Chymotrypsin-like cysteine protease (3CLpro) plays a critical role in viral replication, making it a significant target for therapeutic intervention against COVID-19. This compound is suitable for research applications focused on developing antiviral strategies and studying the mechanistic pathways of viral replication. -
SARS-CoV-2 Inhibitor
Amb929 is a selective inhibitor targeting the nsp3 protein of SARS-CoV-2, demonstrating significant antiviral activity. It effectively inhibits SARS-CoV-2-mNG replication in VeroE6 cells with an EC50 of 34.7 µM and has a moderate cytotoxicity profile, with a CC50 of 281 µM. Additionally, Amb929 shows effectiveness in suppressing viral replication in Human Airway Epithelium (HAE) models, making it a valuable tool for research on COVID-19 and therapeutic development. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2-IN-35 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating a Ki value of 12.1 nM. This compound serves as a valuable tool for investigating the antiviral mechanisms and therapeutic strategies in COVID-19 research. Its oral bioactivity allows for flexible in vivo studies, facilitating the exploration of potential treatments against SARS-CoV-2. -
SARS-CoV-2Inhibitor
SARS-CoV-2-IN-43 is a potent inhibitor of SARS-CoV-2 replication, displaying significant antiviral activity. This compound is valuable for research applications aimed at understanding and mitigating SARS-CoV-2 infection. Its mechanism of action targets key processes in viral replication, making it a crucial tool for studies in virology and therapeutic development against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
AB-343 is a selective covalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2, exhibiting an IC50 of 8 nM and a Ki of 2.8 nM. This compound effectively inhibits the Mpro of SARS-CoV-2 and other coronaviruses, demonstrating activity against certain resistant variants. AB-343 is suitable for research applications focused on therapeutic strategies for coronavirus infection-related diseases. -
Macropinocytosis inhibitor
Virapinib is a potent macropinocytosis inhibitor that demonstrates significant antiviral activity. It effectively inhibits viral entry of a broad range of viruses, including SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, while also enhancing Dengue Virus infection. By obstructing macropinocytosis, Virapinib reduces syncytium formation in SARS-CoV-2-infected cells and hinders the cellular entry of SARS-CoV-2 variants. This compound is valuable for research focused on viral pathogenesis and therapeutic evaluations related to COVID-19 and other viral infections. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-1 (compound 16b-3) is a potent and selective irreversible inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrated by an IC50 of 116 nM. This compound serves as a valuable tool in research targeting SARS-CoV-2, facilitating investigations into viral replication and pathogenesis. Its mechanistic profile makes it suitable for studies aimed at developing antiviral strategies against COVID-19. -
SARS-CoV-2 Mpro Iinhibitor
GC-78-HCl is a nonpeptidic inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 0.19 μM. This compound demonstrates significant antiviral activity and has been characterized by favorable pharmacokinetic properties. It is a valuable reagent for research aimed at exploring therapeutic strategies against SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-66 is a vitamin K derivative and a potent inhibitor of SARS-CoV-2. It exhibits an EC50 value of 70.8 μM in Vero E6/TMPRSS2 cell lines, demonstrating significant antiviral activity. This compound can be utilized in research focused on the development of therapeutic strategies against SARS-CoV-2 infection. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-100 is a potent inhibitor targeting SARS-CoV-2, exhibiting broad-spectrum antiviral activity against multiple variants of the virus. This compound demonstrates synergistic effects when used in combination with Nirmatrelvir, potentially mitigating the risk of antiviral drug resistance. It is suitable for research applications focused on COVID-19 therapeutics and viral replication studies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-76 is a specific inhibitor of the nsp14 viral cap N7 methyltransferase and PLpro, targeting the severe acute respiratory syndrome coronavirus (SARS-CoV-2). This compound demonstrates significant antiviral activity by disrupting key enzymatic processes essential for viral replication. It is a valuable tool for research applications focused on understanding SARS-CoV-2 pathogenesis and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2-IN-80 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 0.964 µM. This compound demonstrates strong antiviral activity, making it a valuable tool for research aimed at unraveling the mechanisms of SARS-CoV-2 replication and pathogenesis. It is suitable for studies focused on developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-75 is a chloroacetamide-based inhibitor targeting SARS-CoV-2. This compound demonstrates significant antiviral activity, inhibiting cellular replication of SARS-CoV-2 with an EC68 value of 3 μM. It is relevant for research applications focused on understanding viral mechanisms and developing therapeutic strategies against COVID-19. -
SARS-CoV-1/2 RdRp Inhibitor
SARS-CoV-IN-6 is a selective inhibitor of the RNA-dependent RNA polymerase (RdRp) of both SARS-CoV-1 and SARS-CoV-2, featuring an IC50 of 7.8 μM against SARS-CoV-2 RdRp. This compound effectively mitigates cytopathic effects in cells infected with SARS-CoV-1 and SARS-CoV-2 replicon-based single-round infectious particles (SRIPs). Additionally, it inhibits the expression of the SARS-CoV N protein, showing EC50 values of 0.12 µM for SARS-CoV-1 SRIPs and 1.47 µM for SARS-CoV-2 SRIPs. SARS-CoV-IN-6 is valuable for research focused on the antiviral mechanisms targeting coronavirus replication. -
SARS-CoV-2 Inhibitor
F8-S40 is a potent inhibitor of the SARS-CoV-2 main protease, demonstrating an IC50 of 10.88 μM. It exhibits significant antiviral activity, making it a valuable tool for researchers investigating COVID-19 therapies. This compound is suitable for studies focused on the inhibition of viral replication and the exploration of new therapeutic strategies against SAR-CoV-2. -
SARS-CoV-2 SP Inhibitor
SP Inhibitor 1 is a selective inhibitor of the SARS-CoV-2 spike protein, exhibiting an IC50 of 3.26 μM, while demonstrating minimal inhibition of Mpro and PLpro above 25 μM. This compound effectively inhibits SARS-CoV-2 replication in vitro at non-toxic concentrations ranging from 0.325 to 5.98 μM. SP Inhibitor 1 possesses significant cellular antiviral activity, making it a valuable tool for research applications focused on understanding and combating SARS-CoV-2. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-20 is a covalent inhibitor of the SARS-CoV-2 3CL protease, with an IC50 of 0.43 μM and a Ki value of approximately 0.33 μM. This compound is essential for investigating the inhibition of the viral protease, which plays a crucial role in the replication of SARS-CoV-2. It serves as a valuable tool in research focused on antiviral drug discovery and the development of therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 Mpro-IN-21 is a highly potent inhibitor of the SARS-CoV-2 Main Protease (MPro), targeting critical viral replication processes. This compound demonstrates significant antioxidant activity, with an IC50 of 0.36 mg/mL in the DPPH assay, indicating its potential in oxidative stress-related research. Furthermore, SARS-CoV-2 Mpro-IN-21 exhibits strong antibacterial activity against Klebsiella, with an IC50 of 1.19 mg/mL, making it a valuable tool for studies in viral and bacterial pathogenesis. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-32 is a selective inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 value of 230 nM. This compound effectively inhibits the replication of various SARS-CoV-2 variants in vitro, making it a valuable tool for studying the virus's biology and testing potential therapeutic strategies against COVID-19. Its specificity towards Mpro positions it as a significant candidate for further research in antiviral drug development. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-56 is a potent inhibitor of SARS-CoV-2, specifically targeting viral replication. This compound demonstrates significant antiviral activity, effectively inhibiting SARS-CoV-2 in Vero E6 cells with an IC50 value of 0.7 μM. It serves as a valuable reagent for research applications focused on understanding SARS-CoV-2 infection mechanisms and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-22 is an inhibitor that targets the entry of SARS-CoV-2 pseudovirus into host cells, exhibiting an IC50 value of 16.96 µM. This compound is valuable for research applications focused on understanding viral entry mechanisms and developing therapeutic strategies against COVID-19. Its effective inhibition supports studies aimed at identifying potential antiviral agents and exploring host-pathogen interactions. -
SARS-CoV-2 Mpro PROTAC degrader
HP211206 is a PROTAC degrader targeting the main protease (Mpro) of SARS-CoV-2, designed to selectively degrade both the protease and its drug-resistant variants. This compound demonstrates an IC50 of 181.9 nM and a DC50 of 621 nM, reflecting its potency in disrupting viral replication. HP211206 also exhibits antiviral activity, making it a valuable tool for research aimed at understanding and combating SARS-CoV-2 infections. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-35 is an inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 0.15 μM. This compound demonstrates potent anti-SARS-CoV-2 activity and effectively inhibits the proliferation of bladder cancer cells while maintaining low cytotoxicity in fibroblasts. It is suitable for research applications focused on SARS-CoV-2 infection and bladder cancer treatment strategies. -
SARS-CoV-2 Mpro Inhibitor
CDD-1819 is a potent non-covalent, non-peptide inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting a Ki of 5 nM. This compound effectively inhibits mutant variants including ΔP168, A173V, and ΔP168/A173V Mpro. CDD-1819 serves as a valuable tool in research focused on COVID-19 therapeutic development and the mechanistic study of viral protease function. -
SARS-CoV-2 Mpro Inhibitor
NVP-EGT710 is an orally active, non-peptidomimetic covalent inhibitor of the SARS-CoV-2 main protease (Mpro). This compound demonstrates potent inhibitory activity against Mpro, making it a valuable tool for studying coronavirus infections. Its mechanism of action and specificity provide a promising avenue for research focused on antiviral therapeutics targeting SARS-CoV-2. -
SARS-CoV-2 Inhibitor
AT-9010 is a triphosphate active metabolite of AT-527 that serves as a potent inhibitor of the NiRAN enzyme, which is essential for the replication of SARS-CoV-2. This compound effectively inhibits the replication of the virus, making it a valuable tool for research into therapeutic strategies targeting COVID-19 and related coronaviruses. Its mechanism of action positions AT-9010 as a promising candidate for advancing our understanding of antiviral therapies. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor targeting the SARS-CoV-2 3CL protease, exhibiting an IC50 of 2.124 μM. This compound selectively binds to the active site of the enzyme, forming a covalent bond with the cysteine residue at position 145. It is a valuable reagent for studying the inhibition of viral replication and may be utilized in research focused on developing antiviral therapies for COVID-19. -
SARS-CoV-2 Proteases Inhibitor
Methyl tanshinonate is a natural product derived from Salvia miltiorrhiza, targeting SARS-CoV-2 proteases. It exhibits potent inhibitory activity against the Mpro enzyme, with an IC50 value of 21.1 µM. This compound holds potential for research applications in the study of SARS-CoV-2 as well as diabetes-related investigations. -
SARS-CoV-2 Mpro Inhibitor
CDD-1733 is a potent non-covalent, non-peptide inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an inhibitory constant (Ki) of 12 nM. This compound is effective against various Mpro variants, including ΔP168, A173V, and ΔP168/A173V. CDD-1733 is essential for research focused on antiviral drug development and the mechanistic study of SARS-CoV-2 pathogenesis. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-57, a potent inhibitor of SARS-CoV-2, exhibits an IC50 value of 80 nM, demonstrating significant antiviral activity. This compound has a high affinity for Sigma receptors, with Ki values of 13.6 nM for the Sigma-1 receptor and 14.4 nM for the Sigma-2 receptor. SARS-CoV-2-IN-57 is specifically designed for research applications focused on understanding and inhibiting SARS-CoV-2 viral mechanisms and interactions. -
SARS-CoV-2 Inhibitor
Z795161988 is a specific inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase, demonstrating an IC50 of 2.2 μM. This compound exhibits significant antiviral activity, making it a valuable tool for research focused on SARS-CoV-2 replication and pathogenesis. Its use in biochemical assays can facilitate the understanding of viral methylation processes and aid in the development of effective therapeutic strategies against COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
3CPLro-IN-2 is a potent inhibitor of the SARS-CoV-2 3CLpro enzyme, demonstrating an IC50 of 1.55 μM and a Ki of 6.09 μM. The 3-chymotrypsin-like cysteine protease plays a crucial role in the viral replication process, making it a compelling target for therapeutic intervention in COVID-19 research. This compound has potential applications in the development of antiviral strategies aimed at mitigating SARS-CoV-2 infection. -
SARS-CoV-2 NPro Inhibitor
SARS-CoV-2-IN-17 is a potent inhibitor of the SARS-CoV-2 nucleocapsid protein (NPro). It demonstrates significant antiviral activity, with an EC50 of 2.18 μM. The compound binds to NPro with a low KD value of 7.82 μM, establishing it as a strong ligand for NPro. This reagent is valuable for research applications targeting SARS-CoV-2 and understanding its viral mechanisms. -
SARS-CoV-2 3CL Protease Inhibitors
MAC-5576 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 81 nM. Additionally, it inhibits HAV 3C protease and thrombin with IC50 values of 0.5 μM and 13 μM, respectively. This compound serves as a valuable tool for research into antiviral therapies and protease inhibition mechanisms, particularly in the context of COVID-19. Its profile supports investigations into viral replication and potential therapeutic strategies. -
SARS-CoV Inhibitor
Isomitomycin A is a potent SARS-CoV-2 inhibitor that targets the hACE2 binding site of the viral spike glycoprotein. This compound demonstrates significant antiviral activity, making it a valuable tool for research into COVID-19 mechanisms and potential therapeutic interventions. Its application in studies related to SARS-CoV-2 reinforces its importance in the ongoing exploration of effective treatments for coronavirus infections. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-17 is a selective inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 0.322 μM. This compound targets the viral protease, disrupting the proteolytic processing of viral polyproteins, thereby inhibiting viral replication. It is a valuable tool for research focused on antiviral drug development and the study of SARS-CoV-2 biology. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 3CLpro-IN-28 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 0.018 μM. This compound effectively disrupts viral replication by targeting the enzymatic function essential for the processing of viral polyproteins. It is a valuable tool for research focused on antiviral strategies and the development of therapeutic agents against COVID-19. -
SARS-CoV-2 Inhibitor
ZINC475239213 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase, exhibiting an IC50 of 20 μM. This compound demonstrates potential antiviral activity by disrupting viral replication mechanisms. It is suitable for research applications focused on COVID-19 and the development of therapeutic strategies against SARS-CoV-2. -
SARS-CoV-2 3Mpro Inhibitor
SARS-CoV-2 Mpro-IN-28 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), with an EC50 value of 24 μM. This compound is essential for studying the replication and pathogenesis of SARS-CoV-2. It plays a significant role in evaluating therapeutic strategies targeting viral protease activity and can facilitate the development of antiviral agents against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-31 is a potent inhibitor of SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 11 nM. This compound also significantly inhibits the enzymatic activity of cysteine proteases cathepsin B and cathepsin L, with IC50 values of 24 nM and 1.8 nM, respectively. Its high specificity and efficacy make SARS-CoV-2 Mpro-IN-31 a valuable tool for research related to coronavirus pathology and enzyme regulation. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-95 is a potent inhibitor of the SARS-CoV-2 papain-like protease (PLpro) with an IC50 value of 0.39 μM. This compound demonstrates significant antiviral activity in mouse models of SARS-CoV-2 infection, making it a valuable tool for research on COVID-19 antiviral strategies and therapeutic development. -
SARS-CoV-2 Inhibitor
RU-0415529 is an orally bioavailable inhibitor targeting SARS-CoV-2 nonstructural protein 14 (NSP14), with an IC50 value of 356 nM. This compound effectively binds to the SAH-stabilized cap binding pocket, disrupting viral RNA methylation and subsequent viral replication. RU-0415529 demonstrates potent anti-infectious activity in mouse models, making it a valuable tool for research on SARS-CoV-2 virology and potential therapeutic applications. -
Anti-SARS-CoV-2 Agent
Apigenin 7,4'-di-O-alloside is a flavonoid glycoside that targets the SARS-CoV-2 virus, demonstrating significant antiviral activity. This compound is of particular interest in research focused on the mechanisms of viral replication and infection. Its potential applications include the investigation of therapeutic strategies for COVID-19 and related viral diseases. -
SARS-CoV-2 Mpro Inhibitor
NZ-804 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 8.9 nM. This compound effectively reduces SARS-CoV-2 replication in HeLa-hACE2 cells, with an EC50 of 14 nM. NZ-804 demonstrates broad-spectrum antiviral activity against various coronaviruses and has been shown to significantly diminish viral replication in mouse and hamster models, making it a valuable tool for research into COVID-19 and related viral infections.
